ASCO 2023 – Novartis’s Adjuvant Breast Cancer Win Comes With Caveats

The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.

Ascos 23 Hallway

Novartis AG’s self-proclaimed hit in the Natalee trial with the breast cancer drug Kisqali was always going to be about the details. Late-breaking results presented at the American Society of Clinical Oncology annual meeting suggest that the Swiss group will have to fight hard to grab share from Eli Lilly and Company and its incumbent Verzenio, and to justify an immediate expansion into new patient groups.

Not that the trial is unsuccessful, with an ASCO abstract describing a solid 25% reduction in the risk of reccurrence...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By 

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Conferences

Post-BIO Podcast: Thoughts From The Frontlines

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

BIO Deal Trends: Financial Market Stress Creates Transactional Opportunities

 
• By 

M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By 

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.